Introduction
============

Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder in a third of cases and results from de novo mutations in the other two-thirds of cases. TSC is associated with cognitive and behavioral changes, and characterized by predisposition to nonmalignant lesions throughout the body, including the kidneys.[@b1-ijnrd-10-091] Renal manifestations are the second most significant cause of morbidity and mortality in patients with TSC, and include renal cysts, angiomyolipomas, fat-poor lesions, and malignant tumors.[@b2-ijnrd-10-091]--[@b4-ijnrd-10-091] These lesions begin in infancy and can become large enough that they can encroach on normal renal tissue, resulting in hypertension and chronic kidney disease (CKD).[@b5-ijnrd-10-091],[@b6-ijnrd-10-091]

TSC is caused by mutations in either the *TSC1* gene, located on chromosome 9 and encoding hamartin, or the *TSC2* gene, located on chromosome 16 and encoding tuberin. Disease-causing mutations can be identified by mutation analysis in 60%--89% of patients who meet the diagnostic criteria for TSC, includinĝ50% with mutations in *TSC2* and 17% with mutations in *TSC1*.[@b7-ijnrd-10-091]--[@b9-ijnrd-10-091] Mutations in *TSC2* tend to result in a more severe clinical phenotype than those in *TSC1*,[@b10-ijnrd-10-091] including the renal involvement.[@b11-ijnrd-10-091],[@b12-ijnrd-10-091] In addition, the gene for autosomal dominant polycystic kidney disease 1 (*PKD1*) lies adjacent to the *TSC2* gene on chromosome 16, and 'contiguous gene deletions' can result in multiple renal cystic lesions, similar to those seen in polycystic kidney disease.[@b13-ijnrd-10-091],[@b14-ijnrd-10-091] This condition is detectable in infancy or early childhood and generally leads to renal insufficiency in the late teens to early 20s.[@b15-ijnrd-10-091]

The renal disorders in TSC are well defined, with the exception of early manifestations of CKD such as proteinuria and hypertension that may be amenable to modification. Because the incidence of early stages of CKD is often asymptomatic, they are not well characterized in these patients. Even less is known about the effect of genotype in these early markers of kidney disease and progression.

This study investigates the presence of proteinuria, reduced glomerular filtration rate (GFR) and hypertension in a cohort of pediatric and young adults with TSC, and examines whether genotype correlates with phenotype.

Patients and methods
====================

We conducted a single-center, retrospective review of children and young adults (aged \<25 years of age) who were followed by the Tuberous Sclerosis Complex Center at NYU School of Medicine. This study was approved by the NYU School of Medicine's Institutional Review Board (IRB). The information was recorded in such a manner that subjects could not be identified, directly or through identifiers linked to the subjects. Therefore, a waiver of authorization for consent was granted by the IRB. The medical record was reviewed to ensure that all subjects had confirmed mutational analysis for TSC. Those without genetic testing were excluded from the study; pregnant patients, patients with primary or secondary causes of nephrotic syndrome, patients with other secondary causes of hypertension, and patients with severe pulmonary manifestations of TSC, specifically those requiring high-frequency oscillation, were also excluded from all analysis. Anthropometric variables and demographic data including age, race, and gender of the children and young adults were recorded. In all patients, the average of office blood pressure measurements on their last three consecutive visits was used for analysis. Guidelines from "The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents"[@b16-ijnrd-10-091] were used to determine if the child or adolescent had hypertension. Diagnostic test results (eg, renal ultrasonography, abdominal magnetic resonance imaging) and laboratory parameters were also tabulated. Proteinuria was estimated using urinalysis when available. Proteinuria on dipstick was reported as negative, 1+ or trace (30 mg/dL), 2+ (100 mg/dL), 3+ (300 mg/dL), or 4+ (1000 mg/dL). None and trace urinary protein were classified as no proteinuria and remaining readings (2+, 3+, and 4+) as proteinuria. The GFR was estimated using the modified Schwartz formula.[@b17-ijnrd-10-091]

Subjects were assigned to one of three groups based on the results of their genetic testing: 1) *TSC1* mutation, 2) *TSC2* mutation, or 3) unidentified mutation. Results were expressed as absolute numbers, proportions, means with standard deviations or medians with range. Nominal variables were analyzed for associations using chi-square test and crude (unadjusted) odds ratio were calculated where appropriate. Interval variables were analyzed using Student's *t*-test for normally distributed variables and Wilcoxon's rank sum test for non-normal distributions. All statistical tests were done using GraphPad Prism version 6.05 for Windows (GraphPad Software, La Jolla CA, USA). *p*\<0.05 was taken as significant.

Results
=======

A total of 84 charts were reviewed as part of this study ([Figure 1](#f1-ijnrd-10-091){ref-type="fig"}). Of these, 49 were excluded due to no documented mutational analysis (36) or age \>25 years at the time of diagnosis (13). Thus, a total of 35 patients fulfilled the inclusion criteria for the study. Seven of these patients had a documented *TSC1* mutation, 22 had a documented *TSC2* mutation, 3 had a non-*TSC1* or *TSC2* documented mutation (1 chromosome 6 mutation, 2 unidentifiable mutations) while 3 patients had unknown mutations by standard genotyping even though there was a characteristic clinical diagnosis of TSC. The greater prevalence of *TSC2* over *TSC1* mutations was consistent with prior studies.[@b9-ijnrd-10-091],[@b11-ijnrd-10-091] The patients were 1--30 years old at the time of study, with a median age of 8 years and an average age of 11 years. Sporadic (de novo) cases accounted 71% of *TSC1* and 52% of *TSC2* patients. Our study population characteristics were similar to those of published case series in terms of distribution of *TSC1* and *TSC2* across age groups and gender ([Table 1](#t1-ijnrd-10-091){ref-type="table"}). Also comparable to large series,[@b11-ijnrd-10-091] there was increased severity of *TSC2*, compared with *TSC1*, disease in multiple organs including the kidneys: 68% of *TSC2* versus 50% of *TSC1* patients had renal involvement ([Figure 2](#f2-ijnrd-10-091){ref-type="fig"}).

Hypertension
------------

Based on office blood pressure measurements, only one patient with *TSC1* was hypertensive, while hypertension was found in 8 out of 22 patients with *TSC2* (36%; [Figure 3](#f3-ijnrd-10-091){ref-type="fig"}). The *TSC1* patient with hypertension did not have renal lesions identified on imaging, while all but one of the hypertensive *TSC2* patients had significant renal lesions identified. None of the hypertensive patients identified was receiving angiotensin-converting enzyme inhibitor or other antihypertensive therapy.

Proteinuria
-----------

Urinalysis was not performed routinely. Only 2 out of 7 patients from the *TSC1* and 12 out of 22 patients from the *TSC2* group had urine specimens, and no significant proteinuria was detected in any patient. The patients with urine specimens had either been referred to pediatric nephrology for follow-up and the urine specimen was obtained by the pediatric nephrologist, had a urinalysis obtained during a hospital admission for a disease complication, or were females in reproductive age receiving intense pharmacological intervention. Only two patients routinely followed by pediatric nephrology had routine spot urine protein and creatinine (Upr/cr) quantitation. The Upr/cr in these two samples was \<0.2 mg/mg.

Glomerular filtration rate
--------------------------

All but one patient with TSC1 mutations had at least one serum creatinine documented in the electronic medical record. The estimated glomerular filtration rate (eGFR) was ≥90 mL/min/1.73 m^2^ in all of them (100%). However, only 15 patients with a *TSC2* mutation had both serum creatinine levels and height documented in the chart for appropriate eGFR calculation. Three of these patients had a low eGFR with two having mild renal impairment and one having moderate renal impairment ([Table 2](#t2-ijnrd-10-091){ref-type="table"}). Serum creatinine was within the normal range in 12 of 15 (80%) patients with *TSC2* mutations ([Table 2](#t2-ijnrd-10-091){ref-type="table"} and [Figure 4](#f4-ijnrd-10-091){ref-type="fig"}). Older patients were more likely to have a low eGFR compared with the younger children. A 7-year-old patient with a *TSC2* mutation had a severe episode of nephrotoxic acute kidney injury with peak serum creatinine of 3.3 mg/dL (eGFR at the time \<30 mL/min/1.73 m^2^) that returned to baseline prior from discharge from the hospital.

Discussion
==========

This study shows a higher prevalence of renal abnormalities in children and young adults with *TSC2* mutations, compared with those with *TSC1* mutations, with significant hypertension in 36% and a low eGFR in 20% in the *TSC2* group. Proteinuria was not consistently measured, but was absent in all patients with urine specimens. However, because of limited testing, we cannot comment on the relative severity of proteinuria in the two *TSC* genotypes.

Current international guidelines for surveillance and management of TSC recommend obtaining abdominal imaging at the time of diagnosis[@b18-ijnrd-10-091] and suggest that magnetic resonance imaging is superior to ultrasound and computed tomography. Magnetic resonance imaging represents the preferred evaluation modality for angiomyolipomas (especially fat-poor lesions). This appears to be consistent in our study -- almost all our patients had one or more renal imaging studies. In addition to imaging, the consensus guidelines suggest assessment of blood pressure and eGFR at diagnosis and annually after that. Clinical guidelines recommend adequate blood pressure control. However, we found a high prevalence of hypertension that was often missed in the clinical setting. It appears that in our population, age-specific criteria for children were not easily accessible and utilized. Patients with hypertension were not treated or referred for further management by pediatric nephrology.

Similar findings apply to the eGFR. Even when the Schwartz formula is incorporated into the medical record system, subtle decreases in eGFR were often missed.

There is no recommendation in the guidelines on the evaluation of proteinuria. While we did not find any patient with significant proteinuria, this may reflect the low rate of screening. Proteinuria is an essential parameter in the detection of early kidney damage that is amenable to intervention, namely use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker to slow progression of CKD. Clinical trials are needed to determine if this intervention is renoprotective and can alter the rate of progression of CKD in patients with TSC.

Study limitations
-----------------

Our study is a small single-center study with a heterogeneous group of children and young adults with TSC followed at an internationally recognized center of excellence for TSC. However, there are limited data about the prevalence of hypertension, proteinuria, and alterations in GFR in the literature. Early findings of renal disease have not received much attention. A finding of increased prevalence of hypertension and decreases in GFR may be important and clinically useful. In light of our finding that proteinuria is not being routinely monitored, large-scale multicenter prospective studies with long-term follow-up could yield more comprehensive reports about the prevalence of hypertension, proteinuria, and rate of decline of renal function and its influence in progression of CKD.

Conclusion
==========

On the basis of eGFR and blood pressures, our findings are consistent with the hypothesis that *TSC2* mutations are associated with earlier and more severe renal involvement in children. There is a great need for closer collaboration between nephrologists and neurologists in the provision of care for pediatric patients with TSC in order to foster adequate screening for early manifestations of renal disease. Furthermore, given the enormous progress in therapies for the complications of TSC, the mechanism of kidney involvement in TSC is shifting as well toward a multifactorial cause -- not only related to genotype but also to the drugs used in the treatment of TSC and its complications. Multidisciplinary TSC centers may improve clinical care for children with TSC and foster natural history studies and clinical trials to improve therapy and outcome.
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###### 

Baseline demographics and clinical characteristics by mutation

  Variables                                                           *TSC1* (n=7)   *TSC2* (n=22)   Non-*TSC1*-Non-*TSC2 mutations* (n=3)   Unknown (n=3)
  ------------------------------------------------------------------- -------------- --------------- --------------------------------------- ---------------
  Age, mean (±SD)                                                     9 (±4.2)       11 (±9.2)       17 (±10)                                19 (±13)
  Male, N (%)                                                         6 (86)         8 (36)          2 (67)                                  1 (33.3)
  Race, N (%)                                                                                                                                
   White                                                              6 (86)         18 (82)         3 (100)                                 3 (100)
   Black                                                              0              3 (13.5)        0                                       0
   Asian                                                              1 (14)         1 (4.5)         0                                       0
  Family history of TSC[a](#tfn1-ijnrd-10-091){ref-type="table-fn"}   2 (28.5)       10 (48)         2 (67)                                  NA
  Renal involvement[b](#tfn2-ijnrd-10-091){ref-type="table-fn"}       3 (50)         13 (68)         1 (33)                                  1 (33)
  Neurological manifest                                               7 (100)        19 (86)         2 (67)                                  3 (100)
  Taking mTOR inhibitor                                               2 (28.5)       3 (13.6)        1 (33)                                  1 (33)

**Notes:**

No family history available for an adopted child with *TSC2*.

No renal imaging available for 1 of the *TSC1* patients and 3 of the *TSC2* patients.

**Abbreviations:** SD, standard deviation; TSC, tuberous sclerosis complex; mTOR, mechanistic target of rapamycin; NA, not applicable.

###### 

Estimated GFRs by mutation

                         *TSC1*, n=6 (%)   *TSC2*, n=15 (%)
  ---------------------- ----------------- ------------------
  Normal GFR (≥90)       6 (100)           12 (80)
  Stage 1 CKD (60--89)   0                 2 (13.3)
  Stage 2 CKD (30--59)   0                 1 (6.6)

**Abbreviations:** CKD, chronic kidney disease; GFR, glomerular filtration rate; TSC, tuberous sclerosis complex.
